JP2022510683A5 - - Google Patents
Info
- Publication number
- JP2022510683A5 JP2022510683A5 JP2021531987A JP2021531987A JP2022510683A5 JP 2022510683 A5 JP2022510683 A5 JP 2022510683A5 JP 2021531987 A JP2021531987 A JP 2021531987A JP 2021531987 A JP2021531987 A JP 2021531987A JP 2022510683 A5 JP2022510683 A5 JP 2022510683A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024077572A JP7720948B2 (ja) | 2018-12-05 | 2024-05-10 | 神経刺激性ステロイド及びその使用方法 |
| JP2025099700A JP2025134803A (ja) | 2018-12-05 | 2025-06-13 | 神経刺激性ステロイド及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862775470P | 2018-12-05 | 2018-12-05 | |
| US62/775,470 | 2018-12-05 | ||
| PCT/US2019/064692 WO2020118060A1 (en) | 2018-12-05 | 2019-12-05 | Neuroactive steroids and their methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024077572A Division JP7720948B2 (ja) | 2018-12-05 | 2024-05-10 | 神経刺激性ステロイド及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022510683A JP2022510683A (ja) | 2022-01-27 |
| JP2022510683A5 true JP2022510683A5 (enExample) | 2022-12-01 |
| JP7539378B2 JP7539378B2 (ja) | 2024-08-23 |
Family
ID=69006056
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531987A Active JP7539378B2 (ja) | 2018-12-05 | 2019-12-05 | 神経刺激性ステロイド及びその使用方法 |
| JP2024077572A Active JP7720948B2 (ja) | 2018-12-05 | 2024-05-10 | 神経刺激性ステロイド及びその使用方法 |
| JP2025099700A Pending JP2025134803A (ja) | 2018-12-05 | 2025-06-13 | 神経刺激性ステロイド及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024077572A Active JP7720948B2 (ja) | 2018-12-05 | 2024-05-10 | 神経刺激性ステロイド及びその使用方法 |
| JP2025099700A Pending JP2025134803A (ja) | 2018-12-05 | 2025-06-13 | 神経刺激性ステロイド及びその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US20230322846A9 (enExample) |
| EP (1) | EP3902818A1 (enExample) |
| JP (3) | JP7539378B2 (enExample) |
| KR (2) | KR20250174100A (enExample) |
| CN (1) | CN113383004A (enExample) |
| AR (1) | AR117264A1 (enExample) |
| AU (3) | AU2019392680B2 (enExample) |
| BR (1) | BR112021010996A2 (enExample) |
| CA (1) | CA3120872A1 (enExample) |
| IL (3) | IL312610B1 (enExample) |
| MA (1) | MA54594A (enExample) |
| MX (4) | MX2021006618A (enExample) |
| TW (2) | TWI874337B (enExample) |
| WO (1) | WO2020118060A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| MX2020006599A (es) * | 2017-12-22 | 2020-11-06 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. |
| TW201930269A (zh) | 2018-01-12 | 2019-08-01 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| WO2020132504A1 (en) * | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| SG11202112391UA (en) | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| CN114729000A (zh) * | 2019-06-27 | 2022-07-08 | 萨奇治疗股份有限公司 | 用于治疗cns病症的化合物 |
| CA3143509A1 (en) * | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2021188778A2 (en) * | 2020-03-18 | 2021-09-23 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CN112679571A (zh) * | 2020-12-24 | 2021-04-20 | 广西壮族自治区中国科学院广西植物研究所 | 一种罗汉果醇衍生物单体、其制备方法及应用 |
| JP2024532273A (ja) * | 2021-08-25 | 2024-09-05 | セージ セラピューティクス， インコーポレイテッド | ポジティブｎｍｄａモジュレート化合物及びその使用方法 |
| CN115974950A (zh) * | 2022-12-23 | 2023-04-18 | 上海彩迩文生化科技有限公司 | 一种3-烷基化的甾体中间体及其制备和应用 |
| JP2026509303A (ja) | 2023-03-14 | 2026-03-17 | キュリア、スペイン、エセ、ア、ウ | ３アルファ－ヒドロキシ－３ベータ－アルキルステロイドを調製するための方法および中間体 |
| WO2024197317A2 (en) * | 2023-03-23 | 2024-09-26 | Emory University | Neurosteroids and prodrugs thereof |
| CN119529013B (zh) * | 2024-11-25 | 2025-11-07 | 湖南新合新生物医药有限公司 | 一种祖拉诺龙中间体的合成方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2969M (fr) * | 1963-05-22 | 1964-11-30 | Roussel Uclaf | Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale. |
| ES432106A1 (es) | 1973-11-30 | 1976-11-01 | Schering Ag | Procedimiento para la preparacion de d-homo-20-cetopregna- nos. |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4060295A (en) | 1976-03-15 | 1977-11-29 | Molex Incorporated | Zero insertion force printed circuit board edge connector assembly |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| NZ298567A (en) * | 1994-11-23 | 2000-01-28 | Cocensys Inc | Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
| FR2967914A1 (fr) | 2010-11-29 | 2012-06-01 | Centre Nat Rech Scient | Composes inhibiteurs d'interactions proteine-proteine ciblant les proteines kinases et leurs applications biologiques |
| EP3572417B1 (en) | 2011-10-14 | 2025-12-17 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| CN117024501A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| WO2017049044A1 (en) * | 2015-09-16 | 2017-03-23 | Bartolucci Giampiero | Ursodeoxycholic acid and brain disorders |
| WO2017187343A2 (en) | 2016-04-29 | 2017-11-02 | Thome Kreutz Fernando | Nanoemulsions and methods for cancer therapy |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| BR112020012761A2 (pt) | 2017-12-22 | 2021-02-17 | Sage Therapeutics, Inc. | composições e métodos para o tratamento de distúrbios do snc |
| US20200384003A1 (en) | 2017-12-29 | 2020-12-10 | Shanghai Lanmu Chemicals Co., Ltd. | Triterpenoid-containing pharmaceutical composition and use thereof |
| WO2019154257A1 (zh) | 2018-02-11 | 2019-08-15 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| EP3852764A4 (en) | 2018-09-19 | 2022-06-15 | ModernaTX, Inc. | STEROL ANALOGUES AND USES THEREOF |
| WO2020132504A1 (en) | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| WO2020210116A1 (en) | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| WO2020210117A1 (en) | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| SG11202113155XA (en) | 2019-05-30 | 2021-12-30 | Intercept Pharmaceuticals Inc | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
| SG11202112391UA (en) | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| CN114729000A (zh) | 2019-06-27 | 2022-07-08 | 萨奇治疗股份有限公司 | 用于治疗cns病症的化合物 |
| WO2021080880A1 (en) | 2019-10-25 | 2021-04-29 | Covey Douglas | Nmdar inhibiting agents and gabaar potentiating agents and uses thereof |
| US20230250129A1 (en) | 2020-06-24 | 2023-08-10 | Sage Therapeutics, Inc. | Neuroactive steroids and compositions thereof |
-
2019
- 2019-12-05 KR KR1020257039569A patent/KR20250174100A/ko active Pending
- 2019-12-05 US US17/311,056 patent/US20230322846A9/en not_active Abandoned
- 2019-12-05 EP EP19828126.3A patent/EP3902818A1/en active Pending
- 2019-12-05 TW TW108144589A patent/TWI874337B/zh active
- 2019-12-05 JP JP2021531987A patent/JP7539378B2/ja active Active
- 2019-12-05 KR KR1020217020784A patent/KR102892974B1/ko active Active
- 2019-12-05 CA CA3120872A patent/CA3120872A1/en active Pending
- 2019-12-05 IL IL312610A patent/IL312610B1/en unknown
- 2019-12-05 IL IL312611A patent/IL312611B2/en unknown
- 2019-12-05 MA MA054594A patent/MA54594A/fr unknown
- 2019-12-05 TW TW114104450A patent/TW202521127A/zh unknown
- 2019-12-05 MX MX2021006618A patent/MX2021006618A/es unknown
- 2019-12-05 AU AU2019392680A patent/AU2019392680B2/en active Active
- 2019-12-05 IL IL283629A patent/IL283629B2/en unknown
- 2019-12-05 CN CN201980091069.0A patent/CN113383004A/zh active Pending
- 2019-12-05 WO PCT/US2019/064692 patent/WO2020118060A1/en not_active Ceased
- 2019-12-05 BR BR112021010996-0A patent/BR112021010996A2/pt unknown
- 2019-12-06 AR ARP190103566A patent/AR117264A1/es unknown
-
2021
- 2021-06-03 MX MX2024004789A patent/MX2024004789A/es unknown
- 2021-06-03 MX MX2024004788A patent/MX2024004788A/es unknown
- 2021-06-03 MX MX2024004790A patent/MX2024004790A/es unknown
-
2023
- 2023-06-13 US US18/334,209 patent/US11912738B2/en active Active
- 2023-06-13 US US18/334,124 patent/US11970514B2/en active Active
- 2023-06-13 US US18/334,189 patent/US11999765B2/en active Active
-
2024
- 2024-03-26 US US18/616,995 patent/US12410210B2/en active Active
- 2024-03-26 US US18/616,762 patent/US12264177B2/en active Active
- 2024-03-26 US US18/616,903 patent/US12252509B2/en active Active
- 2024-05-10 JP JP2024077572A patent/JP7720948B2/ja active Active
-
2025
- 2025-01-14 US US19/019,743 patent/US20250154194A1/en active Pending
- 2025-05-14 AU AU2025203487A patent/AU2025203487A1/en active Pending
- 2025-05-14 AU AU2025203485A patent/AU2025203485A1/en active Pending
- 2025-06-13 JP JP2025099700A patent/JP2025134803A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022510683A5 (enExample) | ||
| JP2022534424A5 (enExample) | ||
| JP2022504607A5 (enExample) | ||
| JP2023537632A5 (enExample) | ||
| JP2021510695A5 (enExample) | ||
| JP2023531517A5 (enExample) | ||
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| RU2506263C2 (ru) | Производные оксазолидиновых антибиотиков | |
| JP2022514385A5 (enExample) | ||
| JP2022538301A5 (enExample) | ||
| JP2018505898A5 (enExample) | ||
| JP2023540344A5 (enExample) | ||
| JP2018502891A5 (enExample) | ||
| RU2018104868A (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2023518411A5 (enExample) | ||
| JP2022538774A5 (enExample) | ||
| RU2015126015A (ru) | Новые улавливатели в лечении макулодистрофии | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2012526728A5 (enExample) | ||
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| JP2017533968A5 (enExample) | ||
| JPWO2020017587A5 (enExample) | ||
| JP2022538299A5 (enExample) | ||
| CA2737999A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |